A

Axiom Bio

AI-driven hepatotoxicity prediction for drugs

Computational Scientist - Biology

Quantitative Biology & BiostatisticsConfirmed live in the last 24 hours
Full-timeSouth San Francisco, CA, USANo salary listedIn-person

About the Job

Requirements

  • Combine deep biological understanding with exceptional computational ability, either as a biologist with strong computational skills or a computational scientist with deep biological fluency.
  • Work directly with raw experimental data and understand how it was generated.
  • Find meaningful signals in complex, noisy biological data and distinguish biological effects from confounding, artifacts, and spurious correlations using sound statistical judgment.
  • Maintain rigorous standards for data quality, reproducibility, and scientific evidence.
  • Connect experimental biology with machine learning and understand how protocols, assay design, feature extraction, and modeling choices shape the conclusions a system can support.
  • Be curious about high-content imaging, transcriptomics, and assay development, and be willing to investigate mechanisms of toxicity across the liver, kidney, heart, and immune system, as well as pharmacokinetics.
  • Critically evaluate how AI models and agents interpret biological evidence, identify reasoning failures, and design experiments and datasets to address those gaps.
  • Use Python and scientific software development tools, including pandas, NumPy, SciPy, and scikit-learn, and create reproducible analytical workflows.
  • Apply statistical inference, experimental design, variance decomposition, dose-response modeling, dimensionality reduction, and predictive modeling with rigorous evaluation.
  • Analyze high-content imaging, morphological profiles, and image-based phenotypes using tools such as CellProfiler, Cellpose, napari, OpenCV, and scikit-image.
  • Analyze and integrate transcriptomic, proteomic, mass spectrometry, ADME, and other complex biological datasets.
  • Use high-throughput screening, assay development, laboratory automation, and methods for assessing experimental quality.
  • Interpret model predictions biologically, including identifying confounding factors, failure modes, and limits to generalization.
  • Communicate scientific findings clearly, turning complex analyses into evidence-grounded explanations.

Responsibilities

  • Lead analysis of large, multimodal toxicity datasets, turning noisy, high-dimensional imaging, transcriptomic, proteomic, and biochemical measurements into biological insights and features for predictive models.
  • Characterize drug responses in primary human cells and multicellular systems, identifying phenotypes associated with mitochondrial dysfunction, cholestasis, lipid accumulation, endoplasmic reticulum stress, and other mechanisms of injury.
  • Develop rigorous quality-control methods to assess reproducibility, batch effects, assay performance, and experimental variability across modalities.
  • Partner with machine-learning scientists to improve models and scientific agents that predict drug toxicity, testing whether predictions reflect meaningful biology and generalize to new compounds.
  • Investigate model behavior, interpret biological signals, and identify failure modes; propose additional measurements to address gaps and lead pilot studies to test their value.
  • Work with experimental scientists to design protocols and assays that capture relevant biology and measurably improve predictive performance.
  • Partner with pharmaceutical and biotech teams to interpret compound toxicity profiles, explain the evidence behind model predictions, and inform drug development decisions.
  • Help build AI systems that explain mechanisms, weigh evidence, and guide the design of safer drugs.

About the Company

Axiom Bio

AI-driven hepatotoxicity prediction for drugs

Axiom Bio provides an AI-driven platform for predictive toxicology that helps drug researchers identify potential liver toxicity early in development. The platform uses a large proprietary dataset—over 115,000 small molecules screened on primary human liver cells with imaging and biochemical readouts, plus PK and clinical data—to predict drug-induced liver injury and related toxicity pathways from a molecule’s structure. It differentiates itself through its large human-toxicity dataset and by offering mechanistic insights (such as mitochondrial toxicity, ER stress, and ROS) at a low per-molecule cost. The goal is to speed up safe drug development by de-risking preclinical pipelines and reducing reliance on animal testing.

Company size
11-50
Company stage
Seed
Total funding
$15M
Headquarters
San Francisco, CA
Founded
2024

Recently Posted Jobs

Explore more opportunities at Axiom Bio

See more jobs